Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Continue

Publications

In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer.

Malla SB. et al, (2021), Clin Cancer Res, 27, 288 - 300

A robust multiplex immunofluorescence and digital pathology workflow for the characterisation of the tumour immune microenvironment.

Viratham Pulsawatdi A. et al, (2020), Mol Oncol

Fusobacterium nucleatum, rectal cancer and radiotherapy.

Mann EH. and Maughan TS., (2020), Ann Oncol

Image-based consensus molecular subtype classification (imCMS) of colorectal cancer using deep learning

VERRILL C. et al, (2020), Gut

A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol.

Brown NF. et al, (2020), BMC Cancer, 20

Exploration of molecular signalling underpinning the DNA Damage Response Deficiency (DDRD) assay in Colorectal Cancer; Data from the S:CORT consortium (Stratification in COlorRecTal cancer)

Malla S. et al, (2019), BRITISH JOURNAL OF CANCER, 121, 3 - 3

Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons.

Hague D. et al, (2019), Trials, 20

Mind the gap? The platform trial as a working environment.

Morrell L. et al, (2019), Trials, 20

This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols.

Schiavone F. et al, (2019), Trials, 20

Molecular biomarkers and precision medicine in colorectal cancer: a systematic review of health economic analyses.

Henderson R. et al, (2019), Oncotarget, 10, 3408 - 3423

Association analyses identify 31 new risk loci for colorectal cancer susceptibility.

Law PJ. et al, (2019), Nat Commun, 10

Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma.

McGowan DR. et al, (2019), Eur J Cancer, 113, 87 - 95

Guidelines for using sigQC for systematic evaluation of gene signatures.

Dhawan A. et al, (2019), Nat Protoc, 14, 1377 - 1400

Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2).

Strauss VY. et al, (2019), BMC Cancer, 19

Pattern Recognition Receptor Polymorphisms as Predictors of Oxaliplatin Benefit in Colorectal Cancer.

Gray V. et al, (2019), J Natl Cancer Inst

SCALOP-2: A randomised trial of induction GEMABX followed by chemoradiation (high/standard dose radiation) +/-nelfinavir for locally advanced pancreatic cancer: results of the dose-finding component

Mukherjee S. et al, (2018)

A phase I dose escalation multi-centre study of crizotinib (MET inhibitor) combined with binimetinib (MEK inhibitor) in patients with advanced solid tumours

Wilson R. et al, (2018), EUROPEAN JOURNAL OF CANCER, 103, E140 - E141

Are All Colorectal Oligometastases Equal?

O'Cathail SM. et al, (2018), INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 102, E14 - E14

Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database.

Salem ME. et al, (2018), Eur J Cancer, 103, 205 - 213

KEAP1-NRF2 Pathway as a Modulator of Response to Radiation in Rectal Cancer

O'Cathail SM. et al, (2018), INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 102, E191 - E192

Load More

1
2
3
4
5
6
7
...
»